AIM2 Inflammasome in Tumor Cells as a Biomarker for Predicting the Treatment Response to Antiangiogenic Therapy in Epithelial Ovarian Cancer Patients

Antiangiogenic therapy, such as bevacizumab (BEV), has improved progression-free survival (PFS) and overall survival (OS) in high-risk patients with epithelial ovarian cancer (EOC) according to several clinical trials. Clinically, no reliable molecular biomarker is available to predict the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Po-Chao, Chao, Tai-Kuang, Chou, Yu-Ching, Yu, Mu-Hsien, Wang, Yu-Chi, Lin, Yi-Hsin, Lee, Yi-Liang, Liu, Li-Chun, Chang, Cheng-Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509490/
https://www.ncbi.nlm.nih.gov/pubmed/34640548
http://dx.doi.org/10.3390/jcm10194529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509490/
https://www.ncbi.nlm.nih.gov/pubmed/34640548
http://dx.doi.org/10.3390/jcm10194529

Ejemplares similares